PDGFRA and gastrointestinal stromal tumor: Avapritinib is a selective, type I PDGFRA-targeted TKI approved by the Food and Drug Administration30 for the treatment of adults with advanced gastrointestinal stromal tumors harboring PDGFRA exon 18 mutations, such as PDGFRA D842V31.